LFA-1 and ICAM-1 antibody-idarubicin conjugates separately prolong murine cardiac allograft survival

被引：3

作者：

Pietersz, GA ^{[1
]}

Sandrin, MS ^{[1
]}

Ling, S ^{[1
]}

Li, YQ ^{[1
]}

McKenzie, IFC ^{[1
]}

机构：

[1] Austin Res Inst, Heidelberg, Vic 3084, Australia

来源：

TRANSPLANT IMMUNOLOGY | 2001年 / 9卷 / 01期

关键词：

immunoconjugates; allograft; idarubicin; monoclonal antibody; ICAM-1; LFA-1;

D O I：

10.1016/S0966-3274(01)00038-7

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Drug antibody conjugates can enhance the activity of monoclonal antibodies (MoAb) and idarubicin-MoAb conjugates have led to tolerance induction with antibodies which are inactive when used alone. It has been reported that, in mice, antibodies to ICAM-1 and LFA-1 have to be used together to induce tolerance to cardiac allografts; here we show that these monoclonal antibodies, conjugated to idarubicin, can lead to tolerance induction to cardiac allografts when used alone. (C) 2001 Elsevier Science B.V. All rights reserved.

引用

页码：7 / 11

页数：5

共 8 条

[1]

CHO CS, 2000, CURR OPIN ORGAN TRAN, V5, P96

[2] SPECIFIC ACCEPTANCE OF CARDIAC ALLOGRAFT AFTER TREATMENT WITH ANTIBODIES TO ICAM-1 AND LFA-1 [J].